uniQure prices IPO at $17, above the range

Comment

Shutterstock photo

uniQure, a biotech developing gene therapies for the treatment of orphan diseases, raised $92 million by offering 5.4 million shares at $17, above the range of $13-$15. uniQure plans to list on the NASDAQ under the symbol QURE. Jefferies and Leerink Partners acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com